Literature DB >> 9268388

Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate.

D M Walsh1, A Lomakin, G B Benedek, M M Condron, D B Teplow.   

Abstract

Fibrillogenesis of the amyloid beta-protein (Abeta) is a seminal pathogenetic event in Alzheimer's disease. Inhibiting fibrillogenesis is thus one approach toward disease therapy. Rational design of fibrillogenesis inhibitors requires elucidation of the stages and kinetics of Abeta fibrillogenesis. We report results of studies designed to examine the initial stages of Abeta oligomerization. Size exclusion chromatography, quasielastic light scattering spectroscopy, and electron microscopy were used to characterize fibrillogenesis intermediates. After dissolution in 0.1 M Tris-HCl, pH 7.4, and removal of pre-existent seeds, Abeta chromatographed almost exclusively as a single peak. The molecules composing the peak had average hydrodynamic radii of 1.8 +/- 0.2 nm, consistent with the predicted size of dimeric Abeta. Over time, an additional peak, with a molecular weight >100,000, appeared. This peak contained predominantly curved fibrils, 6-8 nm in diameter and <200 nm in length, which we have termed "protofibrils." The kinetics of protofibril formation and disappearance are consistent with protofibrils being intermediates in the evolution of amyloid fibers. Protofibrils appeared during the polymerization of Abeta-(1-40), Abeta-(1-42), and Abeta-(1-40)-Gln22, peptides associated with both sporadic and inherited forms of Alzheimer's disease, suggesting that protofibril formation may be a general phenomenon in Abeta fibrillogenesis. If so, protofibrils could be attractive targets for fibrillogenesis inhibitors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9268388     DOI: 10.1074/jbc.272.35.22364

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  283 in total

Review 1.  Amyloid diseases: abnormal protein aggregation in neurodegeneration.

Authors:  E H Koo; P T Lansbury; J W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

2.  Amyloid-beta peptide assembly: a critical step in fibrillogenesis and membrane disruption.

Authors:  C M Yip; J McLaurin
Journal:  Biophys J       Date:  2001-03       Impact factor: 4.033

Review 3.  Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease.

Authors:  P T Lansbury
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

4.  Three-dimensional domain swapping in the folded and molten-globule states of cystatins, an amyloid-forming structural superfamily.

Authors:  R A Staniforth; S Giannini; L D Higgins; M J Conroy; A M Hounslow; R Jerala; C J Craven; J P Waltho
Journal:  EMBO J       Date:  2001-09-03       Impact factor: 11.598

5.  Structure determination of micelle-like intermediates in amyloid beta -protein fibril assembly by using small angle neutron scattering.

Authors:  Winnie Yong; Aleksey Lomakin; Marina D Kirkitadze; David B Teplow; Sow-Hsin Chen; George B Benedek
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-26       Impact factor: 11.205

6.  Conformational characterization of oligomeric intermediates and aggregates in beta-lactoglobulin heat aggregation.

Authors:  R Carrotta; R Bauer; R Waninge; C Rischel
Journal:  Protein Sci       Date:  2001-07       Impact factor: 6.725

7.  An atomic model for the pleated beta-sheet structure of Abeta amyloid protofilaments.

Authors:  L Li; T A Darden; L Bartolotti; D Kominos; L G Pedersen
Journal:  Biophys J       Date:  1999-06       Impact factor: 4.033

Review 8.  Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease.

Authors:  Dennis J Selkoe
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

9.  Effects of the English (H6R) and Tottori (D7N) familial Alzheimer disease mutations on amyloid beta-protein assembly and toxicity.

Authors:  Kenjiro Ono; Margaret M Condron; David B Teplow
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

10.  An improved method for generating consistent soluble amyloid-beta oligomer preparations for in vitro neurotoxicity studies.

Authors:  Deborah A Ryan; Wade C Narrow; Howard J Federoff; William J Bowers
Journal:  J Neurosci Methods       Date:  2010-05-07       Impact factor: 2.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.